Published in Cancer on June 01, 2001
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging (2007) 2.23
Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg (2005) 1.60
Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg (2007) 1.35
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med (2004) 1.33
Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res (2009) 1.30
Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg (2009) 1.27
Neoadjuvant treatment of esophageal cancer. World J Gastroenterol (2010) 1.17
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg (2008) 1.15
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer (2007) 1.05
Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol (2010) 1.03
Multimodality management of esophageal cancer. Indian J Surg Oncol (2013) 1.03
The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer (2007) 1.01
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol (2012) 0.99
Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol (2014) 0.94
The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. Gastrointest Cancer Res (2008) 0.93
FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol (2011) 0.92
Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol (2012) 0.90
[Regression grading of colorectal carcinoma after preoperative radiochemotherapy. An inventory]. Pathologe (2003) 0.90
RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer (2012) 0.89
(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer (2006) 0.89
Chemotherapy as a component of multimodal therapy for gastric carcinoma. World J Gastroenterol (2006) 0.87
Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion. Oncotarget (2015) 0.86
Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus. BMC Cancer (2001) 0.86
Surgical management of esophageal carcinoma. Proc (Bayl Univ Med Cent) (2003) 0.86
Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. Br J Cancer (2012) 0.83
Multimodality management of esophageal cancer. Indian J Surg (2014) 0.83
Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. Medicine (Baltimore) (2015) 0.82
Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis (2008) 0.81
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol (2013) 0.80
Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. Am J Cancer Res (2015) 0.80
Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg (2016) 0.80
State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. J Gastrointest Oncol (2015) 0.80
Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors. Surg Today (2013) 0.78
Interobserver reproducibility of diffusion-weighted MRI in monitoring tumor response to neoadjuvant therapy in esophageal cancer. PLoS One (2014) 0.78
Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma. Sci Rep (2016) 0.78
Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget (2016) 0.77
Preoperative therapy in locally advanced esophageal cancer. World J Gastroenterol (2016) 0.75
Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. Oncotarget (2017) 0.75
Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy. Sci Rep (2017) 0.75
Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. Cancer Invest (2014) 0.75
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol (2017) 0.75
Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy. Int J Clin Oncol (2015) 0.75
Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer. J Thorac Dis (2017) 0.75
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. World J Surg (2017) 0.75
Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg (2017) 0.75
Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis: A systematic review and meta-analysis. Medicine (Baltimore) (2017) 0.75
Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients. Ann Surg (1986) 4.22
Six-year follow-up of the first Waterloo school smoking prevention trial. Am J Public Health (1989) 3.14
Selective therapeutic approach to cancer of the lower esophagus and cardia. J Thorac Cardiovasc Surg (1988) 3.13
Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol (1992) 2.96
Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst (1994) 2.83
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet (1992) 2.44
Randomised controlled trial between stapled circumferential mucosectomy and conventional circular hemorrhoidectomy in advanced hemorrhoids with external mucosal prolapse. Am J Surg (2001) 2.32
Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology (1993) 2.29
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol (1996) 2.24
Chylothorax complicating esophagectomy for cancer: a plea for early thoracic duct ligation. J Thorac Cardiovasc Surg (2000) 2.12
Presentation and surgical management of bronchogenic and esophageal duplication cysts in adults. Chest (1998) 2.07
Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology (1980) 2.04
Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery (1995) 1.99
Delay in the diagnosis and outcome of colorectal cancer: a prospective study. Eur J Surg Oncol (1999) 1.91
Primary treatment of esophageal achalasia. Long-term results of myotomy and Dor fundoplication. Arch Surg (1992) 1.83
Reducing the occupational risk of infections for the surgeon: multicentric national survey on more than 15,000 surgical procedures. World J Surg (1997) 1.83
One-year follow-up after laparoscopic Heller-Dor operation for esophageal achalasia. Surg Endosc (1997) 1.78
Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum (1998) 1.76
Functional evaluation of the intrathoracic stomach as an oesophageal substitute. Br J Surg (1992) 1.75
Natural history and prognostic factors for chronic hepatitis type B. Gut (1991) 1.75
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73
Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis (1991) 1.69
Length of the distal esophageal sphincter and competency of the cardia. Am J Surg (1986) 1.64
Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut (1982) 1.60
A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol (2001) 1.54
Role of acid and bile reflux in development of specialised intestinal metaplasia in distal oesophagus. Dig Liver Dis (2002) 1.49
Temporary double exclusion of the perforated esophagus using absorbable staples. Ann Thorac Surg (1992) 1.44
Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol (1994) 1.43
bcl-2 and p53 immunophenotypes in pre-invasive, early and advanced oesophageal squamous cancer. Histopathology (1997) 1.43
Drug-induced esophageal strictures. Ann Surg (1987) 1.40
Pharyngoesophageal dysfunctions. The role of cricopharyngeal myotomy. Arch Surg (1985) 1.39
Intestinal metaplasia is the probable common precursor of adenocarcinoma in barrett esophagus and adenocarcinoma of the gastric cardia. Cancer (2000) 1.39
Proposal of a modified scintigraphic method to evaluate duodenogastroesophageal reflux. J Nucl Med (1991) 1.39
Hypophosphatemia and renal tubular dysfunction in alcoholics. Are they related to liver function impairment? Gastroenterology (1991) 1.39
Surgical therapy of esophageal leiomyoma. J Am Coll Surg (1995) 1.35
Diverticulectomy, myotomy, and fundoplication through laparoscopy: a new option to treat epiphrenic esophageal diverticula? Ann Surg (1998) 1.32
Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev (2009) 1.25
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis (1987) 1.23
Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc (2001) 1.21
Indications, surgical technique, and long-term functional results of colon interposition or bypass. Ann Surg (1988) 1.19
Esophageal achalasia: laparoscopic versus conventional open Heller-Dor operation. Am J Surg (1995) 1.19
Chronic respiratory symptoms and occult gastroesophageal reflux. A prospective clinical study and results of surgical therapy. Ann Surg (1990) 1.18
Stapled haemorrhoidopexy in fourth degree haemorrhoidal prolapse: is it worthwhile? Colorectal Dis (2006) 1.17
Evaluating results of laparoscopic surgery for esophageal achalasia. Surg Endosc (1998) 1.17
Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg (2000) 1.16
Endoscopic management of inveterate esophageal perforations and leaks. Surg Endosc (1996) 1.14
Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonus epilepsy (EPM1). Exp Cell Res (2001) 1.11
p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer (1997) 1.10
Nuclear matrix protein is released from apoptotic white cells during cold (1-6 degrees C) storage of concentrated red cell units and might induce antibody response in multiply transfused patients. Transfusion (2000) 1.10
Laparoscopic approach to esophageal achalasia. Am J Surg (1995) 1.07
The phosphoenolpyruvate carboxylase gene family of Sorghum: promoter structures, amino acid sequences and expression of genes. Gene (1991) 1.07
Heller laparoscopic cardiomyotomy with antireflux anterior fundoplication (Dor) in the treatment of esophageal achalasia. Surg Endosc (1993) 1.06
The laparoscopic Heller-Dor operation remains an effective treatment for esophageal achalasia at a minimum 6-year follow-up. Surg Endosc (2005) 1.06
Single-layered cervical esophageal anastomoses: a prospective study of two suturing techniques. Ann Thorac Surg (1994) 1.06
CD38 functions are regulated through an internalization step. J Immunol (1998) 1.06
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer (2007) 1.05
The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. Exp Cell Res (1992) 1.05
Minimally invasive surgery for Zenker diverticulum: analysis of results in 95 consecutive patients. Arch Surg (1998) 1.04
Anastomosis. World J Surg (1994) 1.04
Immunocytochemical detection of phosphatidylinositol 4,5-bisphosphate localization sites within the nucleus. J Histochem Cytochem (1995) 1.04
Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci (1991) 1.04
The preS1 domain of hepatitis B virus and IgA cross-react in their binding to the hepatocyte surface. J Gen Virol (1992) 1.03
Targeting of the Akt/PKB kinase to the actin skeleton. Cell Mol Life Sci (2003) 1.03
Molecular alterations of Barrett's esophagus on microdissected endoscopic biopsies. Lab Invest (2001) 1.03
Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients. Ann Oncol (2005) 1.02
Benign tracheoesophageal fistula: results of surgical therapy. Dis Esophagus (1999) 1.01
Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinog (1993) 1.01
The Kagoshima consensus on esophageal achalasia. Dis Esophagus (2011) 1.00
Nuclear changes in a case of X-linked Emery-Dreifuss muscular dystrophy. Muscle Nerve (1999) 1.00
Botulinum toxin injection versus laparoscopic myotomy for the treatment of esophageal achalasia: economic analysis of a randomized trial. Surg Endosc (2004) 1.00
Curative surgery for colorectal cancer: long-term results and life expectancy in the elderly. Dis Colon Rectum (1998) 0.99
Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol (1995) 0.99
Laparotomic vs. laparoscopic rectopexy in complete rectal prolapse. Dig Surg (1999) 0.99